K.J. Harrison & Partners Inc bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,500 shares of the company's stock, valued at approximately $630,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. IFP Advisors Inc lifted its holdings in IDEXX Laboratories by 3.6% in the 4th quarter. IFP Advisors Inc now owns 903 shares of the company's stock worth $373,000 after buying an additional 31 shares in the last quarter. New York Life Investment Management LLC increased its holdings in shares of IDEXX Laboratories by 0.6% in the fourth quarter. New York Life Investment Management LLC now owns 12,279 shares of the company's stock valued at $5,077,000 after buying an additional 77 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $999,000. Metis Global Partners LLC grew its holdings in shares of IDEXX Laboratories by 6.5% during the fourth quarter. Metis Global Partners LLC now owns 5,874 shares of the company's stock valued at $2,429,000 after buying an additional 359 shares in the last quarter. Finally, Middleton & Co. Inc. MA boosted its holdings in shares of IDEXX Laboratories by 98.1% during the fourth quarter. Middleton & Co. Inc. MA now owns 12,305 shares of the company's stock worth $5,087,000 after purchasing an additional 6,095 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.
IDEXX Laboratories Price Performance
IDEXX Laboratories stock traded up $5.02 on Monday, reaching $536.34. The company's stock had a trading volume of 471,085 shares, compared to its average volume of 645,066. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The company has a market cap of $43.13 billion, a price-to-earnings ratio of 49.57, a PEG ratio of 3.88 and a beta of 1.55. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $536.87. The business's fifty day moving average price is $499.01 and its 200 day moving average price is $450.94.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The firm had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period last year, the company earned $2.71 EPS. The business's quarterly revenue was up 3.6% compared to the same quarter last year. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the stock. Stifel Nicolaus raised their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Leerink Partners raised their price target on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Finally, Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $546.00.
Check Out Our Latest Report on IDEXX Laboratories
Insider Buying and Selling at IDEXX Laboratories
In related news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.98% of the stock is currently owned by company insiders.
IDEXX Laboratories Profile
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Read More
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
